JPRN-jRCT2080222858未知1 期
Phase I Study of GDC-0068 as a Single Agent and in Combination with Other Anticancer Drugs in Patients with Advanced Solid Tumors.
CHUGAI PHARMACEUTICAL CO., LTD0 个研究点目标入组 30 人开始时间: 2015年5月22日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •ECOG PS of 0 or 1.
- •- Adequate major organ function.
- •- Stage I: Solid tumor for which standard therapy is ineffective or has not been established.
- •- Stage II: Castration-resistant prostate cancer for which at least one type of hormone therapy is ineffective and the treatment with docetaxel is ineffective or not applicable.
排除标准
- •- Taking oral medication is difficult.
- •- Metastasis to the central nervous system requiring treatment or accompanied by symptoms.
- •- Investigational products or the like with same mode of action were administered, and an adverse event with Grade>=3 severity occurred.
- •- Concurrent or previous clinically critical disease.
- •- Stage I: Women who are pregnant or lactating, or with a positive pregnancy test result.
研究者
相似试验
未知
1 期
PHASE I STUDY OF GDC-0919 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER DRUGS IN PATIENTS WITH ADVANCED SOLID TUMORSJPRN-jRCT2080223275CHUGAI PHARMACEUTICAL CO., LTD.42
进行中（未招募）
1 期
Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors.Advanced HER2-Expressing Solid TumorsMedDRA version: 23.0Level: PTClassification code 10075638Term: HER2 protein overexpressionSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-006812-10-ITBolt Biotherapeutics, Inc.655
进行中（未招募）
1 期
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel ChemotherapyEUCTR2011-004126-10-ESGenentech Inc.258
进行中（未招募）
不适用
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel ChemotherapyCastration-ResistantProstate CancerMedDRA version: 16.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004126-10-NLGenentech Inc.260
进行中（未招募）
1 期
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel ChemotherapyEUCTR2011-004126-10-GRGenentech Inc.273